Carolina Molecular Raises $1.13 Million Seed Round to Expand CLIA-Certified Molecular Testing and Multi-Omic Services
Carolina Molecular, a molecular testing services laboratory with more than 25 years of experience in life sciences, has taken meaningful steps in 2025 to strengthen its operational and financial foundation as demand for clinical sequencing, next-generation sequencing (NGS) and bioinformatics analysis grows among biotechnology, pharmaceutical and research clients. The company, which offers CAP/CLIA-certified and New York State-registered molecular testing along with broad NGS Foundry services, reported raising $1.13 million in a seed funding round from an offering that targeted up to $1.7 million, demonstrating early investor support for its vision to accelerate data-rich molecular profiling and analytical services in translational research, drug development and clinical trial support.
Carolina Molecular was founded to provide comprehensive molecular testing and sequencing services for contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and biotech and pharmaceutical partners. Its laboratory capabilities include whole genome and exome sequencing, single-cell analysis, qPCR, Sanger sequencing, expression profiling and quality control testing, all supported by a team of experienced scientists and bioinformaticians. The company says its approach emphasizes rapid turnaround, flexible service options and integration of advanced analytics, enabling clients to accelerate research and decision-making.
The most recent seed funding, which raised $1.13 million, reflects investor confidence in Carolina Molecular’s ability to expand capacity, enhance its technology stack and support an evolving range of molecular assays in oncology, immunology, infectious disease and cell and gene therapy development. While the detailed list of investors in the seed round has not been publicly disclosed, the capital infusion signals early-stage investor interest in the company’s ability to compete in a growing diagnostics and sequencing market where demand for high-quality, CLIA-certified data services continues to rise.
In addition to private financing, Carolina Molecular has pursued strategic collaborations that broaden its service capabilities and strengthen its value proposition in the life sciences ecosystem. In September 2025, the company announced a strategic partnership with Astoriom, a global expert in stability storage and biorepository services. The collaboration integrates Carolina Molecular’s molecular testing proficiency with Astoriom’s extensive biorepository and cryogenic stability storage solutions across the United States, European Union and United Kingdom, enabling clients to streamline workflows from sample receipt and storage through advanced analysis in a single coordinated process.
Carolina Molecular’s accessible sequencing services and strategic partnerships also extend into emerging areas of multi-omic data generation. In late 2025, the company became the first U.S. certified service provider for Pixelgen Technologies’ advanced Proximity Network Assay, which offers high-resolution protein interactomics analysis for immune cells and other applications. By offering access to these multi-omic assays alongside its established NGS and bioinformatics services, Carolina Molecular is positioning itself to address complex biological questions that span genomics, transcriptomics and proteomics — areas of keen interest in immuno-oncology, cell therapy and biomarker discovery.
The company’s service expansions also include certified service provider status for CS Genetics’ SimpleCell™ single-cell RNA sequencing technology, further broadening its sequencing portfolio and enabling clients to leverage instrument-free, high-throughput single-cell library preparation coupled with robust analytical pipelines. These collaborations enhance Carolina Molecular’s ability to support comprehensive molecular profiling for projects ranging from fundamental biology to clinical applications.
Leadership at Carolina Molecular has emphasized that the combination of seed funding and strategic partnerships positions the company to invest in laboratory infrastructure, expand its client base and pursue additional growth opportunities in the rapidly evolving molecular diagnostics and genomics-services market. The company’s ability to offer CLIA-certified testing and integrated multi-omic solutions — backed by investment capital — underscores its potential to play a key role in supporting translational research efforts, biomarker development and precision medicine initiatives.
As Carolina Molecular enters 2026, the company is poised to build on its early fundraising success and collaborative momentum by continuing to enhance service offerings, attract new biotechnology and pharmaceutical clients, and participate in strategic efforts that align with broader industry trends toward data integration and comprehensive molecular characterization. Its financial and operational investments reflect a broader commitment to helping life sciences teams accelerate discovery and development with high-quality molecular data and analytics.
